US2022202915A1PendingUtilityA1

Sialylated glycoprotein compositons and uses thereof

77
Assignee: ULTRAGENYX PHARMACEUTICAL INCPriority: Mar 5, 2014Filed: Nov 11, 2021Published: Jun 30, 2022
Est. expiryMar 5, 2034(~7.6 yrs left)· nominal 20-yr term from priority
Inventors:Steven JunglesGabrielle MorrisJeff GrubbMichael VellardEmil D. Kakkis
C12N 15/67A61K 38/47A61P 3/00A61K 45/06C12N 9/2402C12Y 302/01031A61K 9/0019C12N 9/2468C12N 9/24A61P 43/00
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present application relates to sialylated glycoprotein compositions and methods of their use in treating various conditions and disorders.

Claims

exact text as granted — not AI-modified
1 .- 27 . (canceled) 
     
     
         28 . A method for treating mucopolysaccharidosis type 7 in a subject in need thereof, comprising administering to the subject a composition comprising a recombinant β-glucuronidase, wherein the recombinant β-glucuronidase is administered every other week by continuous intravenous infusion at a dose of 1 mg/kg to 8 mg/kg. 
     
     
         29 . The method of  claim 28 , wherein the subject is a human. 
     
     
         30 . The method of  claim 28 , wherein the recombinant β-glucuronidase is administered at a dose of 2 mg/kg to 6 mg/kg. 
     
     
         31 . The method of  claim 28 , wherein the recombinant β-glucuronidase is administered at a dose of 4 mg/kg. 
     
     
         32 . The method of  claim 28 , wherein the recombinant β-glucuronidase is administered concurrently with or following antihistamine therapy.

Join the waitlist — get patent alerts

Track US2022202915A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.